

HRQoL scores decrease with treatment line in multiple myeloma

February 13 2019



(HealthDay)—For patients with multiple myeloma (MM), health-related

quality of life (HRQoL) scores decrease with treatment line, according to a study published in the January issue of *Clinical Lymphoma, Myeloma & Leukemia*.

Nicholas Despiégel, from Amgen France in Paris, and colleagues examined the correlations between treatment outcomes and HRQoL in patients with MM in an observational, cross-sectional study. Patients with symptomatic MM who had consulted a physician at least once between February and March 2016 were enrolled. Data were included for 445 patients; 90 percent completed the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) and the Quality of Life Multiple Myeloma module (QLQ-MY20) questionnaire.

The researchers observed a significant decrease in HRQoL with treatment line. Relatively [high scores](#) were seen for patients in the first treatment-free interval; at later lines, better scores were seen for [patients](#) receiving active treatment versus those whose treatment had ended. There was a correlation for high EORTC QLQ-C30 global health status scores with good treatment response, few [adverse events](#), and long duration of treatment; the Eastern Cooperative Oncology Group performance status had a strong influence on global health status scores. There was a correlation for global health status scores with the four items of the QLQ-MY20.

"The observed association between response and HRQoL confirms the clinical relevance to the patient of achieving a deep response to treatment," the authors write.

Several authors disclosed financial ties to pharmaceutical companies.

More information: [Abstract/Full Text](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: HRQoL scores decrease with treatment line in multiple myeloma (2019, February 13)
retrieved 20 April 2024 from

<https://medicalxpress.com/news/2019-02-hrqol-scores-decrease-treatment-line.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.